Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment
- Author:
Gerard ANMELLA
1
;
Alcy MEEHAN
;
Melanie ASHTON
;
Mohammadreza MOHEBBI
;
Giovanna FICO
;
Chee H. NG
;
Michael MAES
;
Lesley BERK
;
Michele De PRISCO
;
Ajeet B. SINGH
;
Gin S. MALHI
;
Michael BERK
;
Seetal DODD
;
Diego HIDALGO-MAZZEI
;
Iria GRANDE
;
Isabella PACCHIAROTTI
;
Andrea MURRU
;
Eduard VIETA
;
Olivia M. DEAN
Author Information
- Publication Type:Original Article
- From:Clinical Psychopharmacology and Neuroscience 2024;22(1):33-44
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Objective:To explore illness-related factors in patients with major depressive disorder (MDD) recipients of adjunctive minocycline (200 mg/day) treatment. The analysis included participants experiencing MDD from a 12-week, double blind, placebo-controlled, randomized clinical trial (RCT).
Methods:This is a sub-analysis of a RCT of all 71 participants who took part in the trial. The impact of illness chronicity (illness duration and number of depressive episodes), systemic illness (endocrine, cardiovascular and obesity), adverse effects and minocycline were evaluated as change from baseline to endpoint (12-week) using ANCOVA.
Results:There was a consistent but statistically non-significant trend on all outcomes in favour of the use of adjunctive minocycline for participants without systemic illness, less illness chronicity, and fewer adverse effects.
Conclusion:Understanding the relationship between MDD and illness chronicity, comorbid systemic illness, and adverse effects, can potentially better characterise those individuals who are more likely to respond to adjunctive anti-inflammatory medications.
